Transitions | Drug Rehabilitation and Immediate Care | Residential Treatment Revenue and Competitors

Erlanger, KY USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Transitions | Drug Rehabilitation and Immediate Care | Residential Treatment's estimated annual revenue is currently $54.4M per year.(i)
  • Transitions | Drug Rehabilitation and Immediate Care | Residential Treatment's estimated revenue per employee is $297,000

Employee Data

  • Transitions | Drug Rehabilitation and Immediate Care | Residential Treatment has 183 Employees.(i)
  • Transitions | Drug Rehabilitation and Immediate Care | Residential Treatment grew their employee count by 76% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$49.9M1687%N/AN/A
#2
$8.6M40-11%N/AN/A
#3
$9.7M455%N/AN/A
#4
$154.6M458N/AN/AN/A
#5
$4.7M259%N/AN/A
#6
$4.9M260%N/AN/A
#7
$12.9M5310%N/AN/A
#8
$5.3M288%N/AN/A
#9
$13.9M578%N/AN/A
#10
$1019.5M269712%N/AN/A
Add Company

What Is Transitions | Drug Rehabilitation and Immediate Care | Residential Treatment?

Addiction Treatment On-Demand A safe and supportive treatment & recovery environment. Addiction is a chronic, progressive, and potentially fatal disease. Individuals who seek treatment for their disease need to start with an initial evaluation by Licensed Clinicians and Medical Team to determine the best course of action and recommendations for care. Plans of care and recommendations need to be individualized and tailored to the person’s clinical and medical needs. Treatment is provided through trauma-informed, person-centered, and recovery-focused services. We believe recovery IS possible with treatment. We understand that recovery is a process and we value and support each person's journey.

keywords:N/A

N/A

Total Funding

183

Number of Employees

$54.4M

Revenue (est)

76%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$58.3M2113%N/A
#2
$35M2812%N/A
#3
$296M783N/AN/A
#4
$276.2M8024%N/A
#5
$410.5M10865%N/A